Literature DB >> 22772472

Palmitoylethanolamide reduces early renal dysfunction and injury caused by experimental ischemia and reperfusion in mice.

Rosanna Di Paola1, Daniela Impellizzeri, Patrizia Mondello, Enrico Velardi, Carmela Aloisi, Alessandro Cappellani, Emanuela Esposito, Salvatore Cuzzocrea.   

Abstract

This study was designed to assess a protective effect of palmitoylethanolamide (PEA) in the development of inflammation after ischemia-reperfusion injury of the kidney. Moreover, to suggest a possible mechanism, renal ischemia-reperfusion was performed in mice with targeted disruption of peroxisome proliferator-activated receptor α (PPAR-α) gene (PPAR-αKO) to explain whether the observed PEA effect was dependent on PPAR-α pathway. Peroxisome proliferator-activated receptor-αKO and littermate wild-type controls (PPAR-αWT) were subjected to bilateral renal artery occlusion (30 min) and reperfusion (6 h) and received PEA (10 mg/kg i.p.) 15 min before release of clamps. Serum and urinary indicators of renal dysfunction and tubular and reperfusion injury were measured, specifically serum urea, creatinine, aspartate aminotransferase and γ-glutamyl transferase, and creatinine clearance. In addition, renal sections were used for histological scoring of renal injury and for immunologic evidence of nitrotyrosine formation, poly[adenosine diphosphate-ribose] (PAR), and adhesion molecules expression. The oxidative stress-sensitive nuclear factor κB signaling pathway was also investigated by Western blot analysis. Kidney myeloperoxidase activity and malondialdehyde levels were measured for assessment of polymorphonuclear leukocyte cell infiltration and lipid peroxidation, respectively. Apoptotic mechanisms were also investigated. Moreover, the infiltration and activation of mast cells were explored. In vivo, PEA administration during ischemia significantly reduced the increase in (i) creatinine, γ-glutamyl transferase, aspartate aminotransferase; (ii) nuclear translocation of nuclear factor κB p65; (iii) kidney myeloperoxidase activity and malondialdehyde levels; (iv) nitrotyrosine, PAR, and adhesion molecules expression; (v) the infiltration and activation of mast cells; and (vi) apoptosis. Our results clearly demonstrate that PEA significantly attenuated the degree of renal dysfunction, injury, and inflammation caused by ischemia-reperfusion injury. Moreover, the positive effects of PEA were at least in part dependent on PPAR-α pathway.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22772472     DOI: 10.1097/SHK.0b013e318267bbb9

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  13 in total

1.  Treatment of chronic regional pain syndrome type 1 with palmitoylethanolamide and topical ketamine cream: modulation of nonneuronal cells.

Authors:  Jan M Keppel Hesselink; David J Kopsky
Journal:  J Pain Res       Date:  2013-03-21       Impact factor: 3.133

2.  A nitric oxide-donor furoxan moiety improves the efficacy of edaravone against early renal dysfunction and injury evoked by ischemia/reperfusion.

Authors:  Fausto Chiazza; Konstantin Chegaev; Mara Rogazzo; Juan C Cutrin; Elisa Benetti; Loretta Lazzarato; Roberta Fruttero; Massimo Collino
Journal:  Oxid Med Cell Longev       Date:  2015-03-05       Impact factor: 6.543

Review 3.  Transcriptomics: A Step behind the Comprehension of the Polygenic Influence on Oxidative Stress, Immune Deregulation, and Mitochondrial Dysfunction in Chronic Kidney Disease.

Authors:  Simona Granata; Alessandra Dalla Gassa; Gloria Bellin; Antonio Lupo; Gianluigi Zaza
Journal:  Biomed Res Int       Date:  2016-06-21       Impact factor: 3.411

Review 4.  Modulation of the Oxidative Stress and Lipid Peroxidation by Endocannabinoids and Their Lipid Analogues.

Authors:  Cristina Anna Gallelli; Silvio Calcagnini; Adele Romano; Justyna Barbara Koczwara; Marialuisa de Ceglia; Donatella Dante; Rosanna Villani; Anna Maria Giudetti; Tommaso Cassano; Silvana Gaetani
Journal:  Antioxidants (Basel)       Date:  2018-07-18

Review 5.  Palmitoylethanolamide: A Natural Compound for Health Management.

Authors:  Paul Clayton; Mariko Hill; Nathasha Bogoda; Silma Subah; Ruchitha Venkatesh
Journal:  Int J Mol Sci       Date:  2021-05-18       Impact factor: 5.923

Review 6.  Palmitoylethanolamide: A Natural Body-Own Anti-Inflammatory Agent, Effective and Safe against Influenza and Common Cold.

Authors:  J M Keppel Hesselink; Tineke de Boer; Renger F Witkamp
Journal:  Int J Inflam       Date:  2013-08-27

7.  L-Arginine Supplementation in Type II Diabetic Rats Preserves Renal Function and Improves Insulin Sensitivity by Altering the Nitric Oxide Pathway.

Authors:  Taylor Claybaugh; Sarah Decker; Kelly McCall; Yuriy Slyvka; Jerrod Steimle; Aaron Wood; Megan Schaefer; Jean Thuma; Sharon Inman
Journal:  Int J Endocrinol       Date:  2014-01-12       Impact factor: 3.257

8.  Cystolithiasis in a Syrian hamster: a different outcome.

Authors:  D Petrini; M Di Giuseppe; G Deli; C De Caro Carella
Journal:  Open Vet J       Date:  2016-08-05

Review 9.  Palmitoylethanolamide, a Natural Retinoprotectant: Its Putative Relevance for the Treatment of Glaucoma and Diabetic Retinopathy.

Authors:  Jan M Keppel Hesselink; Ciro Costagliola; Josiane Fakhry; David J Kopsky
Journal:  J Ophthalmol       Date:  2015-11-18       Impact factor: 1.909

Review 10.  Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy.

Authors:  Linda Gabrielsson; Sofia Mattsson; Christopher J Fowler
Journal:  Br J Clin Pharmacol       Date:  2016-06-29       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.